BMS has also tasked APCO with boosting awareness of hepatitis B, for which it says the Government has no national strategy, despite its increasing prevalence.
Around 180,000 people are infected with the disease in the UK, many from ethnic minority backgrounds.
Led by UK managing director Simon Miller, APCO was hired last month after a competitive pitch.
'APCO demonstrated a strong understanding of our priorities and challenges,' explained the pharma firm's director of external affairs Richard Marsh.
The New England Journal of Medicine issued a study this month warning that BMS's antibiotic product Tequin can have 'life threatening' side effects, including low blood sugar.
The bulk of the company's sales come from prescription drugs.